mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents
Sign Up to like & getrecommendations! Published in 2021 at "NPJ Vaccines"
DOI: 10.1038/s41541-021-00311-w
Abstract: mRNA technologies have recently proven clinical efficacy against coronavirus disease 2019 and are among the most promising technologies to address the current pandemic. Here, we show preclinical data for our clinical candidate CVnCoV, a lipid… read more here.
Keywords: candidate cvncov; virus neutralising; cvncov; sars cov ... See more keywords